Abstract

Introduction: Current guidelines recommend N-terminal pro-brain natriuretic peptide (NT-proBNP) screening to identify subclinical structural cardiac abnormalities in patients at risk for developing clinical heart failure (HF) such as those with diabetes (DM). High-sensitivity cardiac troponin (hs-cTn) is another cardiac biomarker that can predict incident HF in patients with DM. It is unclear how the addition of hs-cTn to NT-proBNP screening impacts the detection of subclinical abnormalities of cardiac structure in patients with DM. Methods: Participants with DM but without known CVD at visit 5 (2011-2013) of the Atherosclerosis Risk in Communities (ARIC) study who had available cardiac biomarker data and detailed echocardiographic assessment were included. The associations of abnormal hs-cTn and/or NT-proBNP (defined as hs-cTn ≥ 6 ng/L and NT-proBNP ≥ 125 pg/mL) with abnormal echocardiographic measures of cardiac structure were assessed using multivariable adjusted linear regression analysis. Results: Participants (N=797, mean age 75±5y, 43% male, 77% White) had mean BMI 31±6 kg/m 2 , systolic blood pressure 129±17 mmHg, and serum creatinine 1.0±0.3 mg/dL. As shown in the table, abnormal NT-proBNP was associated with higher left ventricular (LV) mass, LV end-diastolic volume (EDV), left atrial (LA) volume, and E/A ratio. Abnormal hs-cTn was associated with lower global longitudinal strain (GLS), but no other measures of cardiac structure. The combination of abnormal hs-cTn and NT-proBNP was associated with higher LV EDV and LA volume and lower GLS. Conclusion: Among participants with DM free of CVD, abnormal NT-proBNP was associated with several echocardiographic parameters of abnormal cardiac structure. The addition of hs-cTn to NT-proBNP did not significantly improve detection of structural cardiac abnormalities other than low GLS.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call